

# Marrone Bio Innovations

10:04 14 Jan 2020

## Marrone Bio Innovations gets California Pesticide regulator approval for new bacteria strain

Marrone Bio Innovations Inc. (NASDAQ:MBII), the California biotech firm, has won a key regulatory advance as its new patented bacteria strain *Bacillus* biofungicide Stargus has been formally approved by the California Department of Pesticide Regulation for use by growers in California on a number of crops, including leafy greens and strawberries.

Stargus is in demand as it improves the hardiness of crops, ranging from grapes and brassicas to cucurbits and fruiting vegetables, and controls plant diseases such as white molds.

**READ:** Marrone Bio Innovations boosts credit facility to \$23M

The bacteria has already been approved by the US Environmental Protection Agency and is available on the market across the US and in Mexico, Canada and Puerto Rico. Marrone Bio has also kicked off the process of registering Stargus for sale in other countries as well.

"Trials conducted in the US and specifically in California, have proven Stargus increases crop yields and quality by controlling a variety of plant diseases, including downy mildew, white molds and *Botrytis* gray mold," said Kevin Hammill, chief commercial officer of Marrone Bio Innovation, in a statement. "Stargus used alone outperformed the biological standards and is competitive with the current growers' crop protection chemical standards."


Stargus is part of Marrone Bio's extensive array of 18,000-plus micro-organisms and 350 plant extracts.

Founded in 2006 in Davis, California, Marrone Bio holds more than 400 issued and pending patents and has brought six US Environmental Protection Agency-registered biological product lines and one biostimulant to market. Its suite of biologicals includes a bevy of bacteria strains and plant extracts that fight pests, control plant diseases and reduce stress from sun and water.

**Price:** 1.2

**Market Cap:** \$165.77 m

### 1 Year Share Price Graph



February 2019 August 2019 February 2020

### Share Information

**Code:** MBII

**Listing:** NASDAQ

**52 week High Low**  
1.91 1

**Sector:** Agribusiness

**Website:**  
[www.marronebioinnovations.com](http://www.marronebioinnovations.com)

### Company Synopsis:

*Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth company leading the movement to move a sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment that help customers operate more sustainably while increasing their return on investment.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a

security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Marrone Bio Innovations named herein, including the promotion by the Company of Marrone Bio Innovations in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).